Form 4: Regeneron EVP Joseph LaRosa Sells Shares Under 10b5-1 Plan

Joseph LaRosa, EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,866 shares of common stock at a price of $1,088.95 per share on July 11, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 11, 2024, Joseph LaRosa, the EVP, General Counsel, and Secretary of Regeneron Pharmaceuticals, sold 1,866 shares of common stock.
• The sale was executed at a price of $1,088.95 per share.
• The transaction was conducted under a pre-arranged trading plan compliant with Rule 10b5-1(c), which was adopted on February 16, 2024.
• Following the transaction, LaRosa directly owns 37,937 shares of Regeneron common stock.
• He also indirectly owns 371 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock sale under a pre-arranged trading plan, indicating a neutral sentiment. It doesn't inherently suggest positive or negative implications for the company's performance.

Future Outlook

NA

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. These sales are often pre-planned under Rule 10b5-1 to avoid accusations of insider trading. The volume and frequency of such sales are monitored by investors to gauge executive sentiment and potential impact on stock price.

Comparison to Industry Standards

• Executive stock sales are a routine part of compensation for executives at publicly traded companies like Regeneron.
• Companies such as Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings related to executive stock transactions.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, similar to what is seen at other large pharmaceutical firms.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates